Clinical Trial

Phage Therapy for the Treatment of a Chronic Enterococcus Faecium Periprosthetic Joint Infection

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 24, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of a bacteriophage therapy in a patient with a methicillin-susceptible Enterococcus faecium (E. faecium) prosthetic joint infection (PJI) of the hip. We have exhausted all surgical and medical management of PJI for our patient. The phage will be administered to the study patient during a 14 days period via intravenous and intra-articular. The patient will be monitored in clinic for up to 1 year.
Trial Details
NCT Number NCT06942624
Lead Sponsor Orthopaedic Innovation Centre
Collaborators: Cytophage Technologies Inc., Ottawa Hospital Research Institute
Conditions Periprosthetic Joint Infection
Enrollment 1 participants
Start Date 2025-05
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-04-24